Phase 2 N=60 Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Bipolar Disorder · Obesity
Primary: Percent Change in Body Weight — -3.3; 0.2 % change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Time Restricted Eating Outcomes in Multiple Sclerosis
Multiple Sclerosis · Diet, Healthy
Primary: Timed 25-foot Walk Speed — -.3 feet/second — p=.39
Phase 2 N=5 SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Stage IA Non-Small Cell Lung Carcinoma · Stage IB Non-Small Cell Lung Carcinoma
Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) of Fresolimumab When Combined With SABR (Phase I) — 0 Participants
Phase 2 N=406 Evaluation of S-600918 in Adults With Refractory Chronic Cough
Chronic Cough
Primary: Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment — -55.16; -61.08; -65.32; -60.38 percentage change — p=0.9334
Phase 4 N=65 Preemptive Analgesia With Celecoxib for Acute Dental Pain Management
Pain, Postoperative
Primary: Pain as Assessed by a Visual Analogue Scale (VAS) — 4; 2.33 score on a scale
Phase 4 N=500 A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
Diphtheria
Primary: Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations at Month 11, Based on Per Protocol Set (PPS) — 11.61; 12.66 μg/mL
N/A N=107 EaseVRx for the Reduction of Chronic Pain and Opioid Use
Chronic Low-back Pain
Primary: Pain: Numerical Pain Rating Scale — 0.6; 1.3 units on a scale
Phase 4 N=14 Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
Retinal Detachment
Primary: Post Operative Pain Day 1 — 2.2; 1.0 score on a scale
Phase 2 N=379 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Breast Cancer
Primary: Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months — 53.8; 46.5; 53.0 Percentage of participants
N/A N=25 The iotaSOFT Insertion System Safety Study
Cochlear Implant
Primary: Number of Subjects Experiencing a Peri-procedural Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery — 2 Participants
Phase 3 N=242 A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 7.1; 5.6; 3.7; 5.6 months — p=0.0098
N/A N=6 No Power Bionic Lower Extremity Prosthesis
Amputation · Amputation, Traumatic · Amputation; Traumatic, Leg, Lower
Primary: Peak Propulsive Ground Reaction Force on the Prosthetic Side During Walking — .175; .166; .166 Body-weights
Phase 4 N=66 Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Covid19
Primary: Ratio of 48-Week to Baseline Neutralizing Antibody (NAb) Levels — 0.3722; 0.5883; 0.2088; 0.3073 ratio of geometric mean responses
Phase 2 N=160 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Glioblastoma Multiforme · Glioma · Gliosarcoma
Primary: Frequency of Regimen-Limiting Toxicities (RLTs) in Phase 1 Subjects — 0; 0; 0 Participants
Phase 2 N=132 Management of Severe Acute Malnutrition in SCD, in Northern Nigeria
Sickle Cell Anemia · Severe Acute Malnutrition
Primary: Enrollment Rate at the End of the 6-month Recruitment Period — 111; 22; 110; 22 participants